Multiple myeloma (MM) treatment has changed tremendously, with significant improvement in patient out-comes. One group with a suboptimal benefit is patients with high-risk cytogenetics, as tested by ...

The global molecular cytogenetics market is projected to reach USD 1.43 billion by 2030 from USD 1.02 billion in 2025 at a CAGR of 7.1% from 2025 to 2030. The surge is attributed to rapidly increasing ...